In a step to­ward short­er tu­ber­cu­lo­sis treat­ment, GSK re­ports pos­i­tive mid-stage da­ta for an­tibi­ot­ic

GSK says an ex­per­i­men­tal tu­ber­cu­lo­sis drug has de­liv­ered pos­i­tive re­sults in a Phase IIa, paving the way for com­bi­na­tion reg­i­mens that can be test­ed in Phase IIb/III tri­als.

The can­di­date, dubbed GSK3036656, orig­i­nat­ed from a 11-year col­lab­o­ra­tion with Ana­cor Phar­ma. In the mid-stage study, a low, once-dai­ly oral dose of the drug showed ear­ly bac­te­ri­ci­dal ac­tiv­i­ty af­ter 14 days of treat­ment.

It marks the sec­ond an­tibi­ot­ic win for GSK in days, af­ter the phar­ma gi­ant — one of a few still in this space — claimed suc­cess in two large clin­i­cal tri­als on a new an­tibi­ot­ic for un­com­pli­cat­ed uri­nary tract in­fec­tions. Wrap­ping the tri­als up ear­ly, GSK said it will be fil­ing for FDA ap­proval next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER